This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe
Save the date!
November 6–8, 2023Munich, Germany

Atriva Therapeutics GmbH

Profile

Founded in 2015, Atriva Therapeutics is a biopharmaceutical company specifically pioneering the development of host-targeting antiviral. The company aims to develop new antiviral therapies against different severe respiratory viral infections with a high unmet medical need, such as influenza, hantavirus infections, dengue fever, COVID-19 and other corona viruses.

Atriva’s lead product zapnometinib (INN, previously known as ATR-002) is a first-in-class host-targeting agent which inhibits viral replication and favorably modulates the body’s immune response. Zapnometinib has successfully completed a Phase I trial to demonstrate safety and tolerability in healthy subjects (NCT04385420). Due to its intracellular mechanism of action against replication, Atriva's antiviral zapnometinib avoids resistance and broadens the therapeutic window. A Phase II study RESPIRE  to evaluate efficacy in hospitalized COVID-19 patients demostrated clinical proof-of-concept for hospitalized COVID-19 requiring additional oxygen. The safety profile was very favorable, comparable to Standard-of-Care. A clinical Phase II study PANTHER) including Influenza, COVID-19 and RSV is planned to start in Q1/2023, a. In January 2022, Atriva received an orphan drug designation for its hanta virus program from the FDA.

Due to its mechanism of action offering a dual benefit – antiviral activity and immunomodulation – zapnometinib is uniquely positioned as a promising therapeutic candidate which holds strong potential in the current COVID-19 pandemic and beyond. The small molecule is able to prevent a cytokine storm and accordingly the associated progression to a life-threatening disease in patients with severe virus infections as COVID-19. Treating moderately to severely ill patients aims to reduce the number of critically sick people, which would otherwise be referred to ICUs and require more invasive treatment options. This could fundamentally impact  outcomes for all types of severe respiratory infections coaused by RNA viruses, like Influenza, COVID-19, or RSV and can be vital for national health systems, patients and families.

Atriva Therapeutics owns eleven patent families with broad international coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies. The patent life runs through 2041. The company is located in Frankfurt/Main and Tübingen, Germany.